Polyplus’ LipidBrick IM21.7 is designed to expand the scope of LNP usage in various therapeutic and oncology applications.
Polyplus’ LipidBrick IM21.7 is a novel cationic lipid nanoparticle (LNP) formulation for messenger RNA therapeutic and vaccine development. The formulation is designed to expand the scope of LNP usage in various therapeutic and oncology applications, as well as prophylactic vaccines.
The LipidBrick is designed to overcome current-generation ionizable lipid challenges used in current LNPs by enabling a wider in-vivo biodistribution and decreasing accumulation in the liver. Proof of concept work demonstrated that it successfully modulates the overall charge of LNPs, improving drug efficiency and formulation stability with no additional safety concerns.